News about argenx

argenx reported third-quarter 2026 global product net sales of VYVGART of $1.7 billion, up 54% year over year and 13% quarter over quarter. Positive Phase 3 ALKIVIA results showed consistent treatment effects in IMNM and dermatomyositis, with an sBLA for IMNM on track for submission by year-end 2026. The company submitted an sBLA for ocular myasthenia gravis to the FDA, and a pediatric gMG sBLA was accepted for priority review with a PDUFA target date in February 2027. Phase 3 EMPASSION topline results for empasiprubart in MMN are expected in December 2026, while FB102 is advancing to Phase 3 in celiac disease. argenx continues to target treating 50,000 patients, securing 10 labeled indications and advancing five candidates into registrational development by 2030.